- Home
- FIGS vs ANAB Comparison
FIGS vs ANAB Comparison
Compare FIGS & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIGS
- ANAB
- Stock Information
- Founded
- FIGS 2013
- ANAB 2005
- Country
- FIGS United States
- ANAB United States
- Employees
- FIGS N/A
- ANAB N/A
- Industry
- FIGS Apparel
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- FIGS Consumer Discretionary
- ANAB Health Care
- Exchange
- FIGS Nasdaq
- ANAB Nasdaq
- Market Cap
- FIGS 694.0M
- ANAB 621.1M
- IPO Year
- FIGS 2021
- ANAB 2017
- Fundamental
- Price
- FIGS $5.25
- ANAB $23.17
- Analyst Decision
- FIGS Sell
- ANAB Buy
- Analyst Count
- FIGS 4
- ANAB 10
- Target Price
- FIGS $4.50
- ANAB $44.25
- AVG Volume (30 Days)
- FIGS 1.6M
- ANAB 760.3K
- Earning Date
- FIGS 08-07-2025
- ANAB 08-04-2025
- Dividend Yield
- FIGS N/A
- ANAB N/A
- EPS Growth
- FIGS N/A
- ANAB N/A
- EPS
- FIGS 0.01
- ANAB N/A
- Revenue
- FIGS $561,166,000.00
- ANAB $111,872,000.00
- Revenue This Year
- FIGS $0.72
- ANAB N/A
- Revenue Next Year
- FIGS $2.97
- ANAB $24.39
- P/E Ratio
- FIGS $731.00
- ANAB N/A
- Revenue Growth
- FIGS 3.02
- ANAB 387.20
- 52 Week Low
- FIGS $3.57
- ANAB $12.21
- 52 Week High
- FIGS $7.06
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- FIGS 64.50
- ANAB 56.01
- Support Level
- FIGS $4.98
- ANAB $22.46
- Resistance Level
- FIGS $5.16
- ANAB $24.17
- Average True Range (ATR)
- FIGS 0.22
- ANAB 1.72
- MACD
- FIGS 0.03
- ANAB -0.01
- Stochastic Oscillator
- FIGS 84.03
- ANAB 73.23
About FIGS FIGS Inc.
FIGS Inc is a healthcare apparel company. The Company designs and sells scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear and other apparel. The Company generates maximum revenue from United States. Sales are generated through the Company's digital platforms.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).